Comparison of tests and procedures to build clinically relevant genotypic scores: Application to the Jaguar study

Antiviral Therapy

Volumn 10, Issue 4, 2005, Pages 479-487

  Flandre, Philippe ^a   Marcelin, Anne Geneviève ^b   Pavie, Juliette ^c   Shmidely, Nathalie ^d   Wirden, Marc ^b   Lada, Olivier ^b   Bernard, Marie Charlotte ^d   Molina, Jean Michel ^c   Calvez, Vincent ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d Bristol Myers Squibb France Laboratory   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CODON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; D67N GENE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG SENSITIVITY; GENE; GENE MUTATION; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; K219E GENE; K219Q GENE; K70R GENE; KRUSKAL WALLIS TEST; L210W GENE; L74V GENE; M184T GENE; M184V GENE; M41L GENE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NONHUMAN; PHARMACOGENOMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T215F GENE; T215Y GENE; T69D GENE; TREATMENT FAILURE; V118L GENE;

ANTI-HIV AGENTS; DATA INTERPRETATION, STATISTICAL; DIDANOSINE; DOUBLE-BLIND METHOD; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; RNA, VIRAL; SELECTION (GENETICS);

EID: 23044451326     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP & Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS 2000; 14:F83-89.
2. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R & De Luca A. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS 2002; 16:369-379.
3. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AJ, Graham NM & the VIRA3001 Study Team. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS 2002; 16:579-588.
4. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-2199.
5. Meynard J-L, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-Vézinet F, Clavel F & Girard P-M. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS 2002; 16:727-736.
6. Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M, Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E, Williams I & Youle M. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 2003; 4(Suppl 1):1-41.
7. Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM & Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clinical Infectious Diseases 2003; 37:113-128.
8. Yeni PG, Hammer SM, Carpenter CC, Cooper DA, Fischl MA, Gatell JM, Gazzard BG, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schechter M, Schooley RT, Thompson MA, Vella S & Volberding PA. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel. Journal of the American Medical Association 2002; 288:222-235.
9. Haubrich R & Demeter L. Clinical utility of resistance testing: Retrospective and prospective data supporting use and curent recommendations. Journal of Acquired Immune Deficiency Syndromes 2001; 26:S51-S59.
10. Brun-Vézinet F, Descamps D, Ruffault A, Masquelier B, Calvez V, Peytavin G, Telles F, Morand-Joubert L, Meynard J-L, Vray M, Costagliola D & Narval (ANRS 088) Study Group. Clinically relevant interpretation of genotype for resistance to abacavir. AIDS 2003; 17:1795-1802.
11. Brun-Vézinet F, Costagliola D, Ait Khaled M, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A & DeGrutolla V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004; 9:465-478.
12. Tsai K, Heilek-Snyder G, Evalle F, Su C, Chinn B, Chiu S, Sista P & Cammack N. Predicting phenotypic susceptibility levels of HIV reverse transcriptase and protease from genotype using tree modelling methods. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, San Francisco, USA. Abstract 587.
13. Foulkes AS, De Gruttola V, Hertogs K & Bacheler L. Combining genotype groups and recursive partitioning. 10th Conference on Retroviruses & Opportunistic Infections. 10-14 February 2003, San Francisco, USA. Abstract 121.
14. Tsai K, Heilek-Snyder G, Ravindran P, Hill A, Su C & Chiu S. Changes in genotypic resistance patterns for saquinavir, lopinavir and amprenavir with rising phenotypic cut-off levels: analysis of TORO databases. 13th International HIV Drug Resistance Workshop. 8-12 June 2004, Tenerife, Spain. Abstract 133.
15. Larder BA, Wang D, Revell A, Harrigan R, Montaner J & Lane C. Accuracy of neural network models in predicting HIV treatment response from genotype may depend on diversity as well as size of data sets. 11th Conference on Retroviruses and Opportunistic Infections. 8-11 February 2004, San Francisco, CA, USA. Abstract 697.
16. Marcelin AG, Flandre P, Pavie J, Shmidely N, Wirden M, Lada O, Leleu G, Molina JM & Calvez V. New genotypic score comprising mutations impacting negatively and positively the virological response to didanosine in treatment-experienced patients from the randomized didanosine add on Jaguar study. Antimicrobial Agents & Chemotherapy 2005; 49:1739-1744.
17. Lehmann EL. Nonparametrics: Statistical Methods Based on Ranks. 1975. San Francisco: Holden-Day.
18. Molina JM, Marcelin AG, Pavie J, Heripret L, Merle De Boever C, Troccaz M, Leleu G & Calvez V. Didanosine in HIV-infected patients failing antiretroviral therapy: a randomised placebo-controlled trial. Journal of Infectious Diseases 2005; 191:840-847.
19. Marschner IC, Betensky RA, DeGruttola V, Hammer SM & Kuritzkes DR. Clinical trial using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. Journal of Acquired Immune Deficiency Syndromes 1999; 20:220-227.
20. Flandre P, Durier C, Descamps D, Launay O & Joly V. On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases. Journal of Acquired Immune Deficiency Syndromes 2002; 30:59-64.
21. Flandre P, Alcais A, Descamps D, Moran-Joubert L & Joly V. Estimating and comparing reduction in HIV-1 RNA in clinical trials using methods for interval censored data. Journal of Acquired Immune Deficiency Syndromes 2004; 35:286-292.
22. Update of the Drug Resistance Mutations in HIV-1 2004. http://www.iasusa.org/resistance_mutations/mutations_figures.pdf (accessed November 2004)
23. Jonckheere AR. A distribution-free k-sample test against ordered alternatives. Biometrika 1954; 41:133-145.
24. Sevin AD, DeGruttola V, Nijhuis M, Shapiro JM, Foulkes AS, Para MF & Boucher C. Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. Journal of Infectious Diseases 2000; 182:59-67.
25. Hanna GJ, Johnson VA, Kuritzkes DR, Richman DD, Leigh Brown AJ, Savara AV, Hazelwood JD & D'Aquila RT. Patterns of resistance mutations selected by treatment of human immunodeficiendy virus type 1 infection with zidovudine, didanosine, and nevirapine. Journal of Infectious Diseases 2000; 181:904-911.
26. Marcelin AG, Affolabi D, Lamotte C, Mohand HA, Delaugerre C, Wirden M, Voujon D, Bossi P, Ktorza N, Bricaire F, Costagliola D, Katlama C, Peytavin G & Calvez V. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients. Journal of Medical Virology 2004; 74:16-20.
27. Liu PY, Tsai WY & Wolf M. Design and analysis for survival data under order restrictions with a modified logrank test. Statistics in Medicine 1998; 17:1469-1479.
28. Liu PY, Green S, Wolf M & Crowley J. Testing against ordered alternatives for censored survival data. Journal of the American Statistical Association 1993; 88:153-160.